dynavax.com

Dynavax Technologies

Dynavax Technologies's email is contact@dynavax.com and Dynavax Technologies's phone number is +1 510 848 1327 .

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
View Top Employees for Dynavax Technologies
img Website dynavax.com
img Industry Biotechnology
img Location Emeryville, California, United States
img Employees 222
img HQ 2929 Seventh Street Suite 100
img Phone +1 510 848 1327
img Email contact@dynavax.com
img Funding 1,044,500,000 USD
img Competitors Roche, Agilent Technologies, Amgen, Genentech, Eurofins, Gilead Sciences,
img Website dynavax.com
img Industry Biotechnology
img Location Emeryville, California, United States
img Employees 222
img LinkedIn linkedin.com/company/dynavax-technologies
img HQ 2929 Seventh Street Suite 100
img Phone +1 510 848 1327
img Email contact@dynavax.com
img Funding 1,044,500,000 USD

Top Dynavax Technologies Employees